Show 2 more Monitoring for adverse effects of medications: take into careful consideration the numerous, clinically significant side effects of medications that may be used in the context of COVID-19, as well as drug-drug interactions between medications, both of which may affect COVID-19 symptomatology (including effects on respiratory, cardiac, immune and mental and neurological function). Take into consideration both pharmacokinetic and pharmacodynamic effects. A Monitoring for thromboembolism: monitor patients with COVID-19 for signs or symptoms suggestive of thromboembolism, such as stroke, DVT, PE or acute coronary syndrome. Immediately proceed with appropriate diagnostic and management pathways, if these are clinically suspected. A https://web.pathway.md/diseases/rec2UFiNfrEGXdLl0 28/38 6/29/23, 3:24 AM COVID-19 infection Pathway 12. Quality improvement COVID-19 care pathways: Establish COVID-19 care pathways for patients with suspected or confirmed COVID-19 at local, regional and national levels. A Ensure that community health workers continue to follow usual protocols for recognition and treatment of other common illnesses and danger signs while activating the COVID-19 care pathway (including for referral as needed) for suspect cases. Refer to WHO/IFRC/UNICEF guidance on community-based healthcare, including outreach and campaigns, in the context of the COVID-19 pandemic. A Care bundles: consider using existing care bundles (defined as 3 evidence-informed practices delivered together and consistently to improve care), chosen locally by the hospital or ICU and adapted as necessary for local circumstances, in critically ill patients with COVID-19 with or without invasive mechanical ventilation. C Equipment and care availability: Ensure that all areas, where severe patients may be cared for, are equipped with pulse oximeters, functioning oxygen systems and disposable, single-use, oxygen-delivering interfaces (nasal cannula, Venturi mask and mask with reservoir bag). A Ensure palliative care interventions are accessible at each institution providing care for patients with COVID-19. A Care optimization during pandemic: ensure that hospitals and health systems at local, regional, national and global level have plans, are prepared and ready to surge clinical care capacity (staff, structure, supplies and systems) in order to be able to provide appropriate care of all COVID-19 patients and maintain essential health services. A Show 4 more International classification of diseases coding: use emergency International classification of diseases codes for mortality, as outlined in the International guidance for certification and coding of COVID-19 as cause of death. A Clinical research: As per WHO 2023 guidelines, collect standardized clinical data on all hospitalized patients to improve understanding of the natural history of the disease and contribute data to the WHO Global COVID-19 Clinical Data Platform (see website for details). A As per NIH 2021 guidelines, provide information about ongoing clinical trials of investigational therapies to eligible outpatients with COVID-19 so they can make informed decisions about participating in clinical trials. B Studies 2023 ReCOVer https://web.pathway.md/diseases/rec2UFiNfrEGXdLl0 29/38 6/29/23, 3:24 AM COVID-19 infection Pathway In patients being severely fatigued 3-12 months following COVID-19, CBT was superior to care as usual with respect to reduction in fatigue severity. Tanja A Kuut et al. Clin Infect Dis. 2023 May 8. 2023 BRACE In healthcare workers, BCG vaccine was not superior to placebo with respect to the rate of symptomatic COVID-19 by 6 months. Laure F Pittet et al. N Engl J Med. 2023 Apr 27. Show 60 more References 1. Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker et al. IDSA Guidelines on the Treatment and Management of Patients with COVID 19. IDSA. 2023 May 15. Open 2. Lisa K. Moore, Tobias Tritschler, Shari Brosnahan et al. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. Chest. 2020 Sep; 158 3 1143 1163. Open 3. No authors listed. Therapeutics and COVID 19 living guideline. Geneva: World Health Organization; 2023. Open 4. John B. Lynch, Perica Davitkov, Deverick J. Anderson et al. IDSA Guidelines on Infection Prevention in Patients with Suspected or Known COVID 19. IDSA. 2021 Apr 30;Part 2:v1.0.1. Open 5. No authors listed. Living guidance for clinical management of COVID 19. WHO living guidance. 2023 Jan 13. Open 6. Amir Qaseem, Jennifer Yost, Matthew C Miller et al. Outpatient Treatment of Confirmed COVID 19 Living, Rapid Practice Points From the American College of Physicians Version 1 . Ann Intern Med. 2022 Nov 29. Open 7. National Institutes of Health. Coronavirus Disease 2019 COVID 19 Treatment Guidelines. National Institutes of Health. 2021 Oct. Open 8. Waleed Alhazzani, Laura Evans, Fayez Alshamsi et al. Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 COVID 19 in the ICU First Update. Crit Care Med. 2021 Mar 1;49 3):e219-e234. Open 9. Brewster D, Chrimes N, Do T et al. Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID 19 adult patient group. Med J Aust 2020. Mar 16. Open 10. No authors listed. Drugs to prevent COVID 19 living guideline. Geneva: World Health Organization; 2023. Open 11. Kimberly E Hanson, Angela M Caliendo, Cesar A Arias et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID 19 Molecular Diagnostic Testing. Clin Infect Dis. 2021 Jan 22;ciab048. Open https://web.pathway.md/diseases/rec2UFiNfrEGXdLl0 30/38 6/29/23, 3:24 AM COVID-19 infection Pathway 12. Mary K Hayden, Kimberly E Hanson, Janet A Englund et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID 19 Antigen Testing. Clin Infect Dis. 2023 Jan 26;ciad032. Open 13. Sam Schulman, Michelle Sholzberg, Alex C Spyropoulos et al. ISTH guidelines for antithrombotic treatment in COVID 19. J Thromb Haemost. 2022 Oct;20 10 2214 2225. Open 14. Couper K, Taylor-Phillips S, Grove A et al. COVID 19 infection risk to rescuers from patients in cardiac arrest. Consensus on Science with Treatment Recommendations Internet] Brussels, Belgium: International Liaison Committee on Resuscitation ILCOR , 2020 March 30. Open 15. APSF and partner organisations. Joint Statement on Multiple Patients Per Ventilator. APSF Website 2020. 26 Mar. Open 16. Kimberly E Hanson, Angela M Caliendo, Cesar A Arias et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID 19 Serologic Testing. Clin Infect Dis. 2020 Sep 12;ciaa1343. Open 17. Dominique Farge, Corinne Frere, Jean M Connors et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID 19. Lancet Oncol. 2022 Jul;23 7):e334-e347. Open 18. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID May update on the use of intermediate-intensity anticoagulation in critically ill patients. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID 19 May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Adv. 2021 Oct 26;5 20 3951 3959. Open 19. Sun P, Lu X, Xu C et al. Understanding of COVID 19 based on current evidence. J Med Virol. 2020 Feb 25. Open 20. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease COVID 19 outbreak. J Autoimmun. 2020 Feb 26 102433. Open 21. Wu C, Chen X, Cai Y et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13. Open 22. Arentz M, Yim E, Klaff L et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID 19 in Washington State. JAMA. 2020 Mar 19. Open 23. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS CoV2 may play a role in the respiratory failure of COVID 19 patients. J Med Virol. 2020 Feb 27. Open 24. April Baller, Janet Diaz, Dina Pfeifer et al. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV infection is suspected. Geneva: World Health Organization; 2020. Open 25. Centers for Disease Control and Prevention. Interim Guidance for Discontinuation of Transmission- Based Precautions and Disposition of Hospitalized Patients with COVID 19. CDC Interim Guidance. 2020 Mar. Open 26. Centers for Disease Control and Prevention. Evaluating and Testing Persons for Coronavirus Disease 2019 COVID 19 . CDC Interim Guidance. 2020 Mar. Open 27. Centers for Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 COVID 19 . CDC Interim Guidance. 2020 https://web.pathway.md/diseases/rec2UFiNfrEGXdLl0 31/38 6/29/23, 3:24 AM COVID-19 infection Pathway Feb. Open 28. Alhazzani W et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 COVID 19 . Intensive Care. 2020 Mar. Open 29. Jin YH, Cai L, Cheng ZS et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus 2019-nCoV infected pneumonia (standard version). Mil Med Res. 2020 Feb 6;7 1 4. Open 30. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43 3 185 188. Open 31. Cao B, Wang Y, Wen D et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382 19 1787 1799. Open 32. RECOVERY Collaborative Group, Peter Horby, Wei Shen Lim et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384 8 693 704. Open 33. Carlos Salama, Jian Han, Linda Yau et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021 Jan 7;384 1 20 30. Open 34. Yasmine Gaber. Diarrhoea and the COVID 19 pandemic. Arab J Gastroenterol. 2020 Sep;21 3 146 150. Open 35. Eric J Lenze, Caline Mattar, Charles F Zorumski et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID 19 A Randomized Clinical Trial. JAMA. 2020 Dec 8;324 22 2292 2300. Open 36. Haneen Amawi, Ghina'a I Abu Deiab, Alaa A A Aljabali et al. COVID 19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. Ther Deliv. 2020 Apr;11 4 245 268. Open 37. Wissem Hachfi, Nadia Ben Lasfar. COVID 19 Main therapeutic options. Tunis Med. 2020 Apr;98 4 299 303. Open 38. D Y Wan, X Y Luo, W Dong et al. Current practice and potential strategy in diagnosing COVID 19. Eur Rev Med Pharmacol Sci. 2020 Apr;24 8 4548 4553. Open 39. Viviane C Veiga, Jo o A G G Prats, Danielle L C Farias et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019 randomised controlled trial. BMJ. 2021 Jan 20;372:n84. Open 40. Ventura A Simonovich, Leandro D Burgos Pratx, Paula Scibona et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2021 Feb 18;384 7 619 629. Open 41. John H Stone, Matthew J Frigault, Naomi J Serling-Boyd et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 Dec 10;383 24 2333 2344. Open 42. Henning Bundgaard, Johan Skov Bundgaard, Daniel Emil Tadeusz Raaschou-Pedersen et al. Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS CoV 2 Infection in Danish Mask Wearers A Randomized Controlled Trial. Ann Intern Med. 2020 Nov 18;M20 6817. Open https://web.pathway.md/diseases/rec2UFiNfrEGXdLl0 32/38 6/29/23, 3:24 AM COVID-19 infection Pathway 43. Peter W Horby, Marion Mafham, Jennifer L Bell et al. Lopinavir-ritonavir in patients admitted to hospital with COVID 19 RECOVERY a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct 5;396 10259 1345 1352. Open 44. Derek C Angus, Lennie Derde, Farah Al-Beidh et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID 19 The REMAP CAP COVID 19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020 Oct 6;324 13 1317 1329. Open 45. Spyridon G Deftereos, Georgios Giannopoulos, Dimitrios A Vrachatis et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO 19 Randomized Clinical Trial. JAMA Netw Open. 2020 Jun 1;3 6):e2013136. Open 46. David R Boulware, Matthew F Pullen, Ananta S Bangdiwala et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020 Aug 6;383 6 517 525. Open 47. John H Beigel, Kay M Tomashek, Lori E Dodd et al. Remdesivir for the Treatment of Covid-19 Final Report. N Engl J Med. 2020 Nov 5;383 19 1813 1826. Open 48. Ivan Fan-Ngai Hung, Kwok-Cheung Lung, Eugene Yuk-Keung Tso et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID 19 an open-label, randomised, phase 2 trial. Lancet. 2020 May 30;395 10238 1695 1704. Open 49. Yeming Wang, Dingyu Zhang, Guanhua Du et al. Remdesivir in adults with severe COVID 19 a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 May 16;395 10236 1569 1578. Open 50. Bin Cao, Yeming Wang, Danning Wen et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382 19 1787 1799. Open 51. REMAP CAP Investigators, Anthony C Gordon, Paul R Mouncey et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Apr 22;384 16 1491 1502. Open 52. Adarsh Bhimraj, Rebecca L Morgan, Amy Hirsch Shumaker et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID 19. Clin Infect Dis. 2020 Apr 27;ciaa478. Open 53. Ying-Hui Jin, Lin Cai, Zhen-Shun Cheng et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus 2019-nCoV infected pneumonia (standard version). 10.1186/s40779 020 0233 6. Open 54. C E Coles, C Aristei, J Bliss et al. International Guidelines on Radiation Therapy for Breast Cancer During the COVID 19 Pandemic. Clin Oncol R Coll Radiol). 2020 May;32 5 279 281. Open 55. Geoffrey D Rubin, Christopher J Ryerson, Linda B Haramati et al. The Role of Chest Imaging in Patient Management During the COVID 19 Pandemic: A Multinational Consensus Statement From the Fleischner Society. Chest. 2020 Jul;158 1 106 116. Open 56. Jill R. Dietz, Meena S. Moran, Steven J. Isakoff et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID 19 pandemic. the COVID 19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020; 181 3 487 497. Open 57. L C Poon, H Yang, J C S Lee et al. ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals. Ultrasound Obstet Gynecol. 2020 https://web.pathway.md/diseases/rec2UFiNfrEGXdLl0 33/38 6/29/23, 3:24 AM COVID-19 infection Pathway May;55 5 700 708. Open 58. Elissa Driggin, MD, a et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID 19 Pandemic. J Am Coll Cardiol. 2020 May 12; 75 18 2352 2371. Open 59. Rashid Ali, Fatima Qayyum, Nasir Ahmed et al. Isaric 4c Mortality Score As A Predictor Of In-Hospital Mortality In Covid-19 Patients Admitted In Ayub Teaching Hospital During First Wave Of The Pandemic. J Ayub Med Coll Abbottabad. Jan-Mar 2021;33 1 20 25. Open 60. Chemoprophylaxis, diagnosis, treatments et al. Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID 19 An evidence-based clinical practice guideline (updated version). Mil Med Res. 2020 Sep 4;7 1 41. Open 61. Sherman A Lee. Coronavirus Anxiety Scale: A brief mental health screener for COVID 19 related anxiety. Death Stud. 2020;44 7 393 401. Open 62. David M Levine, Stuart R Lipsitz, Zoe Co et al. Derivation of a Clinical Risk Score to Predict 14 Day Occurrence of Hypoxia, ICU Admission, and Death Among Patients with Coronavirus Disease 2019. J Gen Intern Med. 2021 Mar;36 3 730 737. Open 63. Steve Goodacre, Ben Thomas, Laura Sutton et al. Derivation and validation of a clinical severity score for acutely ill adults with suspected COVID 19 The PRIEST observational cohort study. PLoS One. 2021 Jan 22;16 1):e0245840. Open 64. Guillermo Rodriguez-Nava, Maria Adriana Yanez-Bello, Daniela Patricia Trelles-Garcia et al. Performance of the quick COVID 19 severity index and the Brescia-COVID respiratory severity scale in hospitalized patients with COVID 19 in a community hospital setting. Int J Infect Dis. 2021 Jan;102 571 576. Open 65. Andrea Duca, Simone Piva, Emanuele Foc et al. Calculated Decisions: Brescia-COVID Respiratory Severity Scale BCRSS /Algorithm. Emerg Med Pract. 2020 Apr 16;22 5 Suppl):CD1 CD2. Open 66. Julio Vallejos, Rodrigo Zoni, Mar a Bangher et al. Ivermectin to prevent hospitalizations in patients with COVID 19 IVERCOR COVID19 a randomized, double-blind, placebo-controlled trial. BMC Infect Dis. 2021 Jul 2;21 1 635. Open 67. Adrian D Haimovich, Neal G Ravindra, Stoytcho Stoytchev et al. Development and Validation of the Quick COVID 19 Severity Index: A Prognostic Tool for Early Clinical Decompensation. Ann Emerg Med. 2020 Oct;76 4 442 453. Open 68. Stephen R Knight, Antonia Ho, Riinu Pius et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ. 2020 Sep 9;370:m3339. Open 69. COVID STEROID Trial Group, Marie W Munch, Sheila N Myatra et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID 19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. JAMA. 2021 Nov 9;326 18 1807 1817. Open 70. Gustavo A Ospina-Tasc n, Luis Eduardo Calder n-Tapia, Alberto F Garc a et al. Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID 19 A Randomized Clinical Trial. JAMA. 2021 Dec 7;326 21 2161 2171. Open 71. Eduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID 19 MICHELLE an https://web.pathway.md/diseases/rec2UFiNfrEGXdLl0 34/38 6/29/23, 3:24 AM COVID-19 infection Pathway open-label, multicentre, randomised, controlled trial. Lancet. 2021 Dec 15;S0140 6736 21 02392 8. Open 72. Ang lica Jayk Bernal, Monica M Gomes da Silva, Dany B Musungaie et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022 Feb 10;386 6 509 520. Open 73. Rafael Diaz, Andr s Orlandini, Noelia Castellana et al. Effect of Colchicine vs Usual Care Alone on Intubation and 28 Day Mortality in Patients Hospitalized With COVID 19 A Randomized Clinical Trial. JAMA Netw Open. 2021 Dec 1;4 12):e2141328. Open 74. Robert L Gottlieb, Carlos E Vaca, Roger Paredes et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022 Jan 27;386 4 305 315. Open 75. Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez et al. Early Treatment for Covid-19 with SARS CoV 2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021 Nov 18;385 21 1941 1950. Open 76. Alex C Spyropoulos, Mark Goldin, Dimitrios Giannis et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID 19 The HEP COVID Randomized Clinical Trial. JAMA Intern Med. 2021 Dec 1;181 12 1612 1620. Open 77. INSPIRATION S Investigators. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. BMJ. 2022 Jan 7;376:e068407. Open 78. RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID 19 RECOVERY a randomised, controlled, open-label, platform trial. Lancet. 2022 Jan 8;399 10320 143 151. Open 79. Meagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar et al. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID 19 in Early Asymptomatic SARS CoV 2 Infection: A Randomized Clinical Trial. JAMA. 2022 Feb 1;327 5 432 441. Open 80. Brian M Clemency, Renoj Varughese, Yaneicy Gonzalez-Rojas et al. Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID 19 A Randomized Clinical Trial. JAMA Intern Med. 2022 Jan 1;182 1 42 49. Open 81. Karim Ali, Tanweer Azher, Mahin Baqi et al. Remdesivir for the treatment of patients in hospital with COVID 19 in Canada: a randomized controlled trial. CMAJ. 2022 Feb 22;194 7 E242 E251. Open 82. Jeffrey S Berger, Lucy Z Kornblith, Michelle N Gong et al. Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID 19 A Randomized Clinical Trial. JAMA. 2022 Jan 18;327 3 227 236. Open 83. ITAC INSIGHT Study Group. Hyperimmune immunoglobulin for hospitalised patients with COVID 19 (ITAC a double-blind, placebo-controlled, phase 3, randomised trial. Lancet. 2022 Feb 5;399 10324 530 540. Open 84. E Wesley Ely, Athimalaipet V Ramanan, Cynthia E Kartman et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID 19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022 Apr;10 4 327 336. Open 85. Jean-Fran ois Rossignol, Matthew C Bardin, Jessica Fulgencio et al. A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID 19. EClinicalMedicine. 2022 Feb 28;45 101310. Open https://web.pathway.md/diseases/rec2UFiNfrEGXdLl0 35/38 6/29/23, 3:24 AM COVID-19 infection Pathway 86. REMAP CAP Writing Committee for the REMAP CAP Investigators, Charlotte A Bradbury, Patrick R Lawler et al. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID 19 A Randomized Clinical Trial. JAMA. 2022 Apr 5;327 13 1247 1259. Open 87. Valliappan Muthu, Ritesh Agarwal, Atul Patel et al. Definition, diagnosis, and management of COVID 19 associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. Lancet Infect Dis. 2022 Apr 04. Open 88. Frederick K Korley, Valerie Durkalski-Mauldin, Sharon D Yeatts et al. Early Convalescent Plasma for High-Risk Outpatients with Covid-19. N Engl J Med. 2021 Nov 18;385 21 1951 1960. Open 89. Gilmar Reis, Eduardo A S M Silva, Daniela C M Silva et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19. N Engl J Med. 2022 May 5;386 18 1721 1731. Open 90. Ludger Klimek, Natalija Novak, Eckard Hamelmann et al. Severe allergic reactions after COVID 19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA Position statement of the German Allergy Societies: Medical Association of German Allergologists AeDA , German Society for Allergology and Clinical Immunology DGAKI and Society for Pediatric Allergology and Environmental Medicine GPA . Allergo J Int. 2021;30 2 51 55. Open 91. Oliver Pfaar, Ludger Klimek, Eckard Hamelmann et al. COVID 19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) A Position Paper of the German Society of Allergology and Clinical Immunology DGAKI and the German Society for Applied Allergology AeDA . Allergol Select. 2021 Apr 1;5 140 147. Open 92. Ludger Klimek, Karl-Christian Bergmann, Randolf Brehler et al. Practical handling of allergic reactions to COVID 19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and GAI. Allergo J Int. 2021;30 3 79 95. Open 93. Ludger Klimek, Oliver Pfaar, Margitta Worm et al. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID 19 pandemic: Position paper of rzteverband Deutscher Allergologen AeDA A, Deutsche Gesellschaft f r Allergologie und Klinische Immunologie DGAKI B, Gesellschaft f r P diatrische Allergologie und Umweltmedizin GPA C, sterreichische Gesellschaft f r Allergologie und Immunologie GAI D, Luxemburgische Gesellschaft f r Allergologie und Immunologie LGAI E, sterreichische Gesellschaft f r Pneumologie GP F in co-operation with the German, Austrian, and Swiss ARIA groups G, and the European Academy of Allergy and Clinical Immunology EAACI H. Allergol Select. 2020 Sep 7;4 53 68. Open 94. Ludger Klimek, Oliver Pfaar, Eckard Hamelmann et al. COVID 19 vaccination and allergen immunotherapy AIT A position paper of the German Society for Applied Allergology AeDA and the German Society for Allergology and Clinical Immunology DGAKI . Allergol Select. 2021 Aug 24;5 251 259. Open 95. Ludger Klimek, Oliver Pfaar, Margitta Worm et al. Allergen immunotherapy in the current COVID 19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA Position paper of the German ARIA Group A in cooperation with the Austrian ARIA Group B, the Swiss ARIA Group C, German Society for Applied Allergology AEDA D, German Society for Allergology and Clinical Immunology DGAKI E, Society for Pediatric Allergology GPA F in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO KHC G and the European Academy of Allergy and Clinical Immunology EAACI H. Allergol Select. 2020 May 28;4 44 52. Open https://web.pathway.md/diseases/rec2UFiNfrEGXdLl0 36/38 6/29/23, 3:24 AM COVID-19 infection Pathway 96. WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID 19 final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022 May 21;399 10339 1941 1953. Open 97. Waleed Alhazzani, Ken Kuljit S Parhar, Jason Weatherald et al. Effect of Awake Prone Positioning on Endotracheal Intubation in Patients With COVID 19 and Acute Respiratory Failure: A Randomized Clinical Trial. JAMA. 2022 Jun 7;327 21 2104 2113. Open 98. Cameron R Wolfe, Kay M Tomashek, Thomas F Patterson et al. Baricitinib versus dexamethasone for adults hospitalised with COVID 19 ACTT 4 a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022 May 23;S2213 2600 22 00088 1. Open 99. Hugh Montgomery, F D Richard Hobbs, Francisco Padilla et al. Efficacy and safety of intramuscular administration of tixagevimab cilgavimab for early outpatient treatment of COVID 19 TACKLE a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022 Oct;10 10 985 996. Open 100. Guylaine Labro, Florence Tubach, Lisa Belin et al. Nicotine patches in patients on mechanical ventilation for severe COVID 19 a randomized, double-blind, placebo-controlled, multicentre trial. Intensive Care Med. 2022 Jun 9;1 12. Open 101. ACTIV Therapeutics for Inpatients with COVID TICO Study Group. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID 19 a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2022 Oct;10 10 972 984. Open 102. Monika Tandon, Wen Wu, Keith Moore et al. SARS CoV 2 accelerated clearance using a novel nitric oxide nasal spray NONS treatment: A randomised trial. Lancet Reg Health Southeast Asia. 2022 Jun 29;3 100036. Open 103. Mitra K Nadim, Lui G Forni, Ravindra L Mehta et al. COVID 19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative ADQI Workgroup. Nat Rev Nephrol. 2020 Dec;16 12 747 764. Open 104. Carolyn T Bramante, Jared D Huling, Christopher J Tignanelli et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. 2022 Aug 18;387 7 599 610. Open 105. Erin A Bohula, David D Berg, Mathew S Lopes et al. Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID 19 COVID PACT. Circulation. 2022 Nov;146 18 1344 1356. Open 106. Lamontagne F et al. Corticosteroids for COVID 19. WHO Living Guidance. Sept 2020. Open 107. Theodoros Karampitsakos, Ourania Papaioannou, Panagiota Tsiri et al. Tocilizumab versus baricitinib in hospitalized patients with severe COVID 19 an open label, randomized controlled trial. Clin Microbiol Infect. 2022 Oct 20;S1198 743X 22 00529 8. Open 108. Shruti Gupta, Jake J Lee, Amber Perrin et al. Efficacy and Safety of Saline Nasal Irrigation Plus Theophylline for Treatment of COVID 19 Related Olfactory Dysfunction: The SCENT2 Phase 2 Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2022 Sep 1;148 9 830 837. Open 109. Susanna Naggie, David R Boulware, Christopher J Lindsell et al. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID 19 A Randomized Clinical Trial. JAMA. 2022 Oct 25;328 16 1595 1603. Open https://web.pathway.md/diseases/rec2UFiNfrEGXdLl0 37/38 6/29/23, 3:24 AM COVID-19 infection Pathway 110. Meg J Jardine, Sradha S Kotwal, Abhinav Bassi et al. Angiotensin receptor blockers for the treatment of covid-19 pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. BMJ. 2022 Nov 16;379:e072175. Open 111. Mark Loeb, Amy Bartholomew, Madiha Hashmi et al. Medical Masks Versus N95 Respirators for Preventing COVID 19 Among Health Care Workers. Ann Intern Med. 2022 Dec;175 12 1629 1638. Open 112. Christopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID 19 at increased risk of adverse outcomes PANORAMIC an open-label, platform-adaptive randomised controlled trial. Lancet. 2022 Dec 22;S0140 6736 22 02597 1. Open 113. Tatjana Welzel, Andrew Atkinson, Nina Sch bi et al. Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS CoV 2 PIMS TS an open-label, multicentre, randomised trial. Lancet Child Adolesc Health. 2023 Feb 3;S2352 4642 23 00020 2. Open 114. writing committee for the BCG PRIME study group, Writing committee, Eva L Koekenbier et al. Bacillus Calmette-Gu rin vaccine for prevention of COVID 19 and other respiratory tract infections in older adults with comorbidities: a randomized controlled trial. Clin Microbiol Infect. 2023 Jan 31;S1198 743X 23 00044 7. Open 115. Zhujun Cao, Weiyi Gao, Hong Bao et al. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N Engl J Med. 2023 Feb 2;388 5 406 417. Open 116. Tracy Y Wang, Abdus S Wahed, Alison Morris et al. Effect of Thromboprophylaxis on Clinical Outcomes After COVID 19 Hospitalization. Ann Intern Med. 2023 Mar 21;M22 3350. Open 117. Gilmar Reis, Eduardo Augusto Dos Santos Moreira Silva, Daniela Carla Medeiros Silva et al. Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID 19 A Randomized Platform Trial. Ann Intern Med. 2023 May;176 5 667 675. Open 118. Laure F Pittet, Nicole L Messina, Francesca Orsini et al. Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers. N Engl J Med. 2023 Apr 27;388 17 1582 1596. Open 119. Tanja A Kuut, Fabiola M ller, Irene Csorba et al. Efficacy of cognitive behavioral therapy targeting severe fatigue following COVID 19 results of a randomized controlled trial. Clin Infect Dis. 2023 May 8;ciad257. Open 120. Yasmin Maor, Eilat Shinar, Marina Izak et al. A Randomized Controlled Study Assessing Convalescent Immunoglobulins versus Convalescent Plasma for Hospitalized COVID 19 Patients. Clin Infect Dis. 2023 May 23;ciad305. Online ahead of print. Open https://web.pathway.md/diseases/rec2UFiNfrEGXdLl0 38/38